Ratings Surperformance

Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
-

Ratings ESG MSCI

Ratings Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited: Strengths and Weaknesses

Highlights: Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Weaknesses: Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
  • The company's earnings growth outlook lacks momentum and is a weakness.

Rating Financials

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited SectorChina

Fundamentals

-

Growth

Revenue growth

EPS growth

FCF growth

-

Profitability

EBITDA Margin

-

EBIT Margin

Net Margin

Capital Efficiency

-

ROA

-

ROCE

-

ROE

Financial Health

-

Gearing

-

Leverage

-

Capital Intensity

-

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

-

Long term EPS growth

More ratings

Rating Valuation

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited SectorChina

Global Valuation

-

Enterprise value

-

EV/Revenue

-

EV/EBITDA

-

EV/FCF

-

Equity Valuation

-

P/E

PBR

-

Dividend Yield

-

EV/EBIT

-

CAPEX/Revenue

More ratings

Rating Consensus

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited SectorChina

Consensus

-

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

-

Analysts' target price evolution (1 year)

-

Analysts' target price evolution (4 months)

-

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

-
More ratings

Rating Business Predictability

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited SectorChina

Visibility

-

Analysts' coverage

Financial estimates divergence

-

Analysts' recommendations divergence

Analysts' Target price divergence

-

Surprise rates

Rating Revisions

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited SectorChina

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
4.23B - - - - - -
13.35B
A
5.5B
BBB
4.93B
BB
4.06B
BB
-
3.83B -
B
- - - -
3.21B -
2.45B - - - - - - -
1.86B - - - - - - -
1.83B - -
Average 4.52B
BBB
Weighted average by Cap.
BBB
  1. Stock Market
  2. Equities
  3. 600329 Stock
  4. Ratings Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited